# Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK

> **NCT06358573** · PHASE2 · RECRUITING · sponsor: **Swiss Cancer Institute** · enrollment: 61 (estimated)

## Conditions studied

- Triple-negative Breast Cancer
- TNBC - Triple-Negative Breast Cancer

## Interventions

- **DRUG:** INT230-6
- **OTHER:** neoadjuvant immuno-chemotherapy

## Key facts

- **NCT ID:** NCT06358573
- **Lead sponsor:** Swiss Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-24
- **Primary completion:** 2028-10
- **Final completion:** 2031-12
- **Target enrollment:** 61 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06358573

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06358573, "Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06358573. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*